An Open Trial of Octreotide Long-Acting Release in the Management of Short Bowel Syndrome

Abstract

Sandostatin LAR Depot for 15 wk significantly prolonged small bowel transit time. Body weight and stool parameters in response to Sandostatin LAR Depot treatment needs to be assessed further in multicenter studies assessing dose, frequency of administration, and a larger sample size.